首页> Clinical lymphoma, myeloma & leukemia> Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

导出原文传递

翻译打印收藏纠错

第一作者： Weisel, Katja

作者： Weisel, Katja ^[1] ; Krishnan, Amrita ^[2] ; Schecter, Jordan M. ^[3] ; Vogel, Martin ^[4] ; Jackson, Carolyn C. ^[5] ; Deraedt, William ^[6] ; Yeh, Tzu-min ^[7] ; Banerjee, Arnob ^[8] ; Yalniz, Fevzi ^[9] ; Nesheiwat, Tonia ^[10] ; Van Sanden, Suzy ; Diels, Joris ; Valluri, Satish ; Usmani, Saad Z. ; Berdeja, Jesus G. ; Jagannath, Sundar ; Martin, Tom

作者单位： University of Hamburg,Univ Med Ctr Hamburg Eppendorf ^[1] Judy & Bernard Briskin Ctr Multiple Myeloma Res,City Hope Natl Med Ctr ^[2] Janssen R&D ^[3] Levine Canc Inst Atrium Hlth ^[4] Sarah Cannon Res Inst ^[5] Mt Sinai Med Ctr ^[6] UCSF Helen Diller Family Comprehens Canc Ctr ^[7] Janssen Global Serv LLC ^[8] Legend Biotech USA Inc ^[9] Janssen Pharmaceut NV ^[10]

关键词 Cilta-cel Indirect comparison RRMM OUTCOMES

发布时间 2023-02-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交